Table 1

Demographic and clinical features of patients with PsA, nonpsoriatic SpA (AS + USpA) and RA.

Parameter

PsA

Nonpsoriatic SpA

RA

Number of patient

22

28

52

Sex (male/female)

14/8

22/6

25/27

Age (years)

45.6 ± 11.0

43.3 ± 13.7

54.0 ± 14.9

Disease duration (years)

10.1 ± 11.5

8.4 ± 9.8

4.9 ± 6.2

Number of swollen joints

4.1 ± 4.0

3.7 ± 4.0

10.5 ± 6.8

Serum CRP (mg/dl)

2.1 ± 1.9

4.0 ± 5.8

6.0 ± 7.4

ESR (mm/hour)

23.6 ± 22.2

30.1 ± 30.5

35.7 ± 27.1

Rheumatoid factor (+/-)

0/21

1/26

36/13

NSAID (+/-)

15/7

25/3

38/14

DMARD (+/-)

6/16

7/21

21/31

Corticosteroids (+/-)

1/21

2/26

12/40

The nonpsoriatic SpA subgroup includes 13 patients with AS and 15 with USpA. Values are expressed as mean ± standard deviation or as numbers. AS, ankylosing spondylitis; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; NSAID, nonsteroidal anti-inflammatory drug; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, spondyloarthropathy; USpA, undifferentiated spondyloarthropathy.

Kruithof et al. Arthritis Research & Therapy 2005 7:R569   doi:10.1186/ar1698